{"organizations": [], "uuid": "ab838b8ded9bc4dc44344b258a95546655501d78", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-revance-reports-qtrly-net-loss-per/brief-revance-reports-qtrly-net-loss-per-share-attributable-to-common-stockholders-1-14-idUSASB0C83M", "country": "US", "domain_rank": 408, "title": "BRIEF-Revance Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $1.14", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.352, "site_type": "news", "published": "2018-03-01T05:57:00.000+02:00", "replies_count": 0, "uuid": "ab838b8ded9bc4dc44344b258a95546655501d78"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-revance-reports-qtrly-net-loss-per/brief-revance-reports-qtrly-net-loss-per-share-attributable-to-common-stockholders-1-14-idUSASB0C83M", "ord_in_thread": 0, "title": "BRIEF-Revance Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $1.14", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "revance therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 28 (Reuters) - Revance Therapeutics Inc:\n* REVANCE RELEASES FOURTH QUARTER AND FULL YEAR 2017 RESULTS\n* REVANCE THERAPEUTICS INC - ‍REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018​\n* REVANCE THERAPEUTICS INC - QTRLY BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS $1.14\n* REVANCE THERAPEUTICS INC - ‍EXPECTS CASH BURN FOR 2018 TO BE IN RANGE OF $117 TO $137 MILLION​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-01T05:57:00.000+02:00", "crawled": "2018-03-01T21:15:08.027+02:00", "highlightTitle": ""}